A Phase 2 interventional study of eltrombopag 12.5 milligrams (mg) tablet and eltrombopag 25 mg tablet in Liver Diseases, sponsored by GlaxoSmithKline. Completed at 10 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-05-12.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Liver Diseases with a site in Japan — 4 open to participants now, 4 under way, 1 of them phase 3. Liver Diseases · Japan.
Among the 14 studies in Liver Diseases with a site in Japan, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2009, is one of 4 in phase 2, and was the 4th registered.
825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.
Browse Liver Diseases studies →4 of the 14 studies in Liver Diseases with a site in Japan are open now. Recruiting first, the newest first:
AusperBio Therapeutics Inc. · Sites in Japan, Australia, China and 4 more countries
Ages 18–65
Boston Scientific Corporation · Sites in Japan
Ages 18+
Hoffmann-La Roche · Sites in Japan, United States, Argentina and 24 more countries
Ages 18–80
European Foundation for Study of Chronic Liver Failure · Sites in Japan, United States, Argentina and 24 more countries
Ages 18–80
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 52 across 522 interventional studies indexed under Liver Diseases.
Median enrollment 77 across the 12 interventional studies, 2,075 across the 2 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 7 studies filed under Liver Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Liver Diseases with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07377487Boston Scientific CorporationTheraSphere Japan Pre-Market Study | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Liver Diseases with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open label, multi-centre, dose ranging study to assess efficacy, safety and pharmacokinetics of eltrombopag in thrombocytopenic subjects with chronic liver disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non- (i.e., physiologically incapable of becoming pregnant) including any female who:
Childbearing potential, has a negative urine and/or serum pregnancy test at screening, and within the 24 hour period prior to the first dose of product and uses one of the following acceptable methods of :
Exclusion Criteria:
AND ≥ two of the following risk factors:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
eltrombopag 12.5 mg/day
Drug: eltrombopag 12.5 milligrams (mg) tablet
eltrombopag 25 mg/day
Drug: eltrombopag 25 mg tablet
eltrombopag 37.5 mg/day
Drug: eltrombopag 12.5 milligrams (mg) tablet · Drug: eltrombopag 25 mg tablet
eltrombopag 12.5 mg tablet once a day
eltrombopag 25 mg tablet once a day
Change From Baseline in Platelet Counts on Day 15
Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.
Time frame: Baseline, Day 15
Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline Platelet Counts as Covariate)
Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.
Time frame: Baseline, Day 15
Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline of Platelet Counts and Child-Pugh Class as Covariates)
Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts and Child-Pugh class as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.
Time frame: Baseline, Day 15
Percent Change From Baseline in Platelet Counts on Day 15
Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.
Time frame: Baseline, Day 15
Platelet Counts by Treatment Visit
Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.
Time frame: Day 1 (Baseline), Day 8, Day 15, and Final Assessment Point (Day 15 or Day 22)
Platelet Counts by Post-Treatment Visit
Platelet counts were measured by blood draw.
Time frame: 4 days post-treatment, 8 days post-treatment, and 15 days post-treatment
Platelet Counts at Day 22
Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.
Time frame: Day 22
Change From Baseline in Platelet Counts by Treatment Visit
Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22. Change from Baseline was calculated as the value at each visit minus the Baseline value.
Time frame: Baseline, Day 8, Day 15, and Final Assessment Point (Day 15 or Day 22)
Change From Baseline in Platelet Counts by Post-Treatment Visit
Platelet counts were measured by blood draw. Change from Baseline was calculated as the value at each visit minus the Baseline value.
Time frame: 4 days post-treatment, 8 days post-treatment, and 15 days post-treatment
Percentage of Responders on Day 15
A responder was defined as a participant with a platelet count within the target range (\>=80 x 10\^9/Liter) on Day 15.
Time frame: Day 15
Percentage of Responders on Day 22
A responder was defined as a participant with a platelet count within the target range (\>=80 x 10\^9/Liter) on Day 22 after receiving eltrombopag for an additional week from Day 15, on which his or her platelet count was \<80 x 10\^9/Liter.
Time frame: Day 22
Change From Baseline in Platelet Counts on Day 15 by Child-Pugh Class
Change from Baseline was calculated as the Day 15 value minus the Baseline value. The Child-Pugh (CP) score (ranging from 5 to 15, with 5 being mild and 15 being severe), calculated based on total bilirubin, serum albumin, international normalized ratio, ascites, and hepatic encephalopathy, is used to assess the severity of liver disease. A CP score of 5 or 6 is classified as Class A (mild), a score of 7-9 is classified as Class B (moderate), and a score \>=10 is classified as Class C (severe). Participants with a CP score \<10 were enrolled in the study.
Time frame: Baseline, Day 15
Change From Baseline in Platelet Counts on Day 15 by Sex
Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of females and males in each treatment group are illustrated by the "n's" in the category titles.
Time frame: Baseline, Day 15
Change From Baseline in Platelet Counts on Day 15 by Age
Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of participants in each age category are illustrated by the "n's" in the category titles.
Time frame: Baseline, Day 15
Log-transformed Cmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg
Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Cmax=maximum drug concentration.
Time frame: Day 14, Day 15
Log-transformed Tmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg
Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Tmax=maximum drug concentration time.
Time frame: Day 14, Day 15
Log-transformed AUC(0-t) and AUC(0-24) on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg
Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. AUC(0-t)=area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration, and AUC(0-24)=area under the concentration-time curve from 0 (pre-dose) to 24 hours.
Time frame: Day 14, Day 15
| Milestone | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Started | 12 | 14 | 12 |
| Completed | 12 | 14 | 12 |
| Not completed | 0 | 0 | 0 |
Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.
| 10^9/Liter | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Change From Baseline in Platelet Counts on Day 15 | 24.8 (8.2 to 41.4) | 54.0 (28.2 to 79.8) | 60.0 (29.3 to 90.7) |
Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.
| 10^9/Liter | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline Platelet Counts as Covariate) | 24.8 (8.2 to 41.4) | 54.0 (28.2 to 79.8) | 60.0 (29.3 to 90.7) |
Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts and Child-Pugh class as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.
| 10^9/Liter | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline of Platelet Counts and Child-Pugh Class as Covariates) | 24.8 (8.2 to 41.4) | 54.0 (28.2 to 79.8) | 60.0 (29.3 to 90.7) |
Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.
| Percent change | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Percent Change From Baseline in Platelet Counts on Day 15 | 57.86 (18.77 to 96.94) | 134.57 (81.36 to 187.78) | 158.45 (92.32 to 224.59) |
Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.
| 10^9/Liter | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Day 1 | 42.5 (36 to 49) | 38.0 (19 to 48) | 40.0 (23 to 49) |
| Day 8 | 50.5 (37 to 73) | 49.5 (27 to 88) | 52.0 (32 to 87) |
| Day 15 | 66.0 (37 to 126) | 73.0 (31 to 232) | 81.5 (53 to 242) |
| Final Assessment Point | 66.0 (37 to 126) | 95.5 (35 to 232) | 85.5 (57 to 242) |
Platelet counts were measured by blood draw.
| 10^9/Liter | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| 4 days post-treatment, n=12, 13, 11 | 63.5 (41 to 173) | 100.0 (38 to 271) | 109.0 (59 to 372) |
| 8 days post-treatment, n=12, 13, 12 | 67.5 (46 to 178) | 119.0 (40 to 387) | 120.0 (66 to 376) |
| 15 days post-treatment, n=11, 13, 11 | 65.0 (36 to 157) | 87.0 (29 to 382) | 97.0 (59 to 295) |
Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.
| 10^9/Liter | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Platelet Counts at Day 22 | — | 82.5 (35 to 126) | 72.5 (57 to 88) |
Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22. Change from Baseline was calculated as the value at each visit minus the Baseline value.
| 10^9/Liter | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Day 8 | 6.9 ± 9.43 | 14.6 ± 11.80 | 15.4 ± 8.96 |
| Day 15 | 24.8 ± 26.13 | 54.0 ± 44.70 | 60.0 ± 48.36 |
| Final Assessment Point | 24.8 ± 26.13 | 64.0 ± 42.51 | 61.9 ± 47.77 |
Platelet counts were measured by blood draw. Change from Baseline was calculated as the value at each visit minus the Baseline value.
| 10^9/Liter | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| 4 days post-treatment, n=12, 13, 11 | 33.0 ± 36.36 | 73.8 ± 50.14 | 97.6 ± 83.38 |
| 8 days post-treatment, n=12, 13, 12 | 41.5 ± 40.50 | 100.9 ± 81.96 | 108.3 ± 81.26 |
| 15 days post-treatment, n=11, 13, 11 | 35.7 ± 36.58 | 82.2 ± 83.13 | 83.0 ± 68.31 |
A responder was defined as a participant with a platelet count within the target range (\>=80 x 10\^9/Liter) on Day 15.
| percentage of responders | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Percentage of Responders on Day 15 | 25.0 (5.5 to 57.2) | 42.9 (17.7 to 71.1) | 58.3 (27.7 to 84.8) |
A responder was defined as a participant with a platelet count within the target range (\>=80 x 10\^9/Liter) on Day 22 after receiving eltrombopag for an additional week from Day 15, on which his or her platelet count was \<80 x 10\^9/Liter.
| percentage of responders | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Percentage of Responders on Day 22 | — | 50.0 (11.8 to 88.2) | 50.0 (1.3 to 98.7) |
Change from Baseline was calculated as the Day 15 value minus the Baseline value. The Child-Pugh (CP) score (ranging from 5 to 15, with 5 being mild and 15 being severe), calculated based on total bilirubin, serum albumin, international normalized ratio, ascites, and hepatic encephalopathy, is used to assess the severity of liver disease. A CP score of 5 or 6 is classified as Class A (mild), a score of 7-9 is classified as Class B (moderate), and a score \>=10 is classified as Class C (severe). Participants with a CP score \<10 were enrolled in the study.
| 10^9/Liter | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Child-Pugh Class A, n=8, 8, 7 | 24.4 ± 32.51 | 44.5 ± 27.02 | 66.6 ± 60.59 |
| Child-Pugh Class B, n=4, 6, 5 | 25.8 ± 5.97 | 66.7 ± 61.93 | 50.8 ± 27.23 |
Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of females and males in each treatment group are illustrated by the "n's" in the category titles.
| 10^9/Liter | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Female, n=4, 4, 4 | 47.3 ± 31.16 | 83.5 ± 69.67 | 98.8 ± 65.18 |
| Male, n=8, 10, 8 | 13.6 ± 15.03 | 42.2 ± 26.96 | 40.6 ± 23.81 |
Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of participants in each age category are illustrated by the "n's" in the category titles.
| 10^9/Liter | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| <65 years of age, n=7, 11, 5 | 19.7 ± 23.34 | 40.2 ± 24.50 | 49.8 ± 30.36 |
| >=65 years of age, n=5, 3, 7 | 32.0 ± 30.82 | 104.7 ± 71.32 | 67.3 ± 59.36 |
Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Cmax=maximum drug concentration.
| nanograms/milliliter (ng/ml) | Eltrombopag 12.5 mg |
|---|---|
| Log-transformed Cmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg | 3412.999 (2549.0060 to 4569.8448) |
Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Tmax=maximum drug concentration time.
| hours | Eltrombopag 12.5 mg |
|---|---|
| Log-transformed Tmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg | 3.444 (2.4593 to 4.8226) |
Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. AUC(0-t)=area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration, and AUC(0-24)=area under the concentration-time curve from 0 (pre-dose) to 24 hours.
| hours * ng/ml | Eltrombopag 12.5 mg |
|---|---|
| AUC(0-t) | 65244.180 (46617.4188 to 91313.5730) |
| AUC(0-24) | 65235.699 (46748.123 to 91034.594) |
Collected over The time period of detecting adverse events (AEs) and serious adverse events (SAEs) was from the start of eltrombopag (Day 1) treatment to 15 days post-treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag 12.5 mg | — | 0/12 (0%) | 6/12 (50%) |
| Eltrombopag 25 mg | — | 0/14 (0%) | 7/14 (50%) |
| Eltrombopag 37.5 mg | — | 1/12 (8.3%) | 9/12 (75%) |
| Event | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| AscitesGastrointestinal disorders | 0/12 | 0/14 | 1/12 |
| Event | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg |
|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1/12 | 0/14 | 4/12 |
| Postoperative feverInjury, poisoning and procedural complications | 3/12 | 0/14 | 2/12 |
| PyrexiaGeneral disorders | 0/12 | 3/14 | 2/12 |
| Abdominal distensionGastrointestinal disorders | 1/12 | 0/14 | 2/12 |
| Procedural painInjury, poisoning and procedural complications | 2/12 | 0/14 | 1/12 |
| Alanine aminotransferase increasedInvestigations | 2/12 | 1/14 | 0/12 |
| Aspartate aminotransferase increasedInvestigations | 2/12 | 1/14 | 0/12 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/12 | 0/14 | 2/12 |
| AscitesGastrointestinal disorders | 1/12 | 0/14 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 1/12 | 1/14 | 1/12 |
| Age, Continuous(years) | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg | Total |
|---|---|---|---|---|
| Mean | 62.2 ± 10.51 | 57.7 ± 8.69 | 66.3 ± 8.84 | 61.8 ± 9.78 |
| Sex: Female, Male(Participants) | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg | Total |
|---|---|---|---|---|
| Female | 4 | 4 | 4 | 12 |
| Male | 8 | 10 | 8 | 26 |
| Race/Ethnicity, Customized(participants) | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg | Total |
|---|---|---|---|---|
| Asian-Japanese Heritage | 12 | 14 | 12 | 38 |
| Number of participants categorized into the indicated Child-Pugh (CP) Class(participants) | Eltrombopag 12.5 mg | Eltrombopag 25 mg | Eltrombopag 37.5 mg | Total |
|---|---|---|---|---|
| Class A | 8 | 8 | 7 | 23 |
| Class B | 4 | 6 | 5 | 15 |
| Class C | 0 | 0 | 0 | 0 |
The record gives a start of Jan 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eltrombopag